“A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis”
This is a phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.
Drug - Upadacitinib (ABT-494)
Upadacitinib is administered orally
Drug - Dupilumab
Dupilumab is administered as a subcutaneous (SC) injection
Drug - Placebo
Placebo pre-filled syringe is administered as subcutaneous (SC) injections
Drug - Placebo
Placebo tablets are administered orally
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
NCT03738397
bDkYna